SCHEMBL29853333

SCHEMBL29853333

Cc1cc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)ccc1C(N)=O

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTK2 Q05397 20/20 0.86
▸ AURKA O14965 1/20 0.73
▸ JAK2 O60674 1/20 0.73
▸ STK16 O75716 1/20 0.73
▸ CDKL5 O76039 1/20 0.73
▸ LATS1 O95835 1/20 0.73
▸ PAK4 O96013 1/20 0.73
▸ ABL1 P00519 1/20 0.73
▸ NTRK1 P04629 1/20 0.73
▸ CDK1 P06493 1/20 0.73
▸ LYN P07948 1/20 0.73
▸ RET P07949 1/20 0.73
▸ ADORA3 P0DMS8 1/20 0.73
▸ FER P16591 1/20 0.73
▸ FLT1 P17948 1/20 0.73
▸ ERCC2 P18074 1/20 0.73
▸ CSNK2A2 P19784 1/20 0.73
▸ CCNA2 P20248 1/20 0.73
▸ DRD1 P21728 1/20 0.73
▸ CDK2 P24941 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1627370 1.00 PTK2 (0.86) PTK2AURKAJAK2STK16CDKL5
SCHEMBL29853792 0.92 PTK2 (1.00) PTK2AURKAJAK2STK16CDKL5
SCHEMBL29853286 0.92 PTK2 (1.00) PTK2AURKAJAK2STK16CDKL5
SCHEMBL1628560 0.92 PTK2 (1.00) PTK2AURKAJAK2STK16CDKL5
SCHEMBL1627078 0.92 PTK2 (1.00) PTK2AURKAJAK2STK16CDKL5
SCHEMBL29853259 0.92 PTK2 (1.00) PTK2AURKAJAK2STK16CDKL5
SCHEMBL1626939 0.92 PTK2 (1.00) PTK2AURKAJAK2STK16CDKL5
SCHEMBL1627095 0.92 PTK2 (0.84) PTK2AURKAJAK2STK16CDKL5
SCHEMBL1628463 0.91 PTK2 (1.00) PTK2AURKAJAK2STK16CDKL5
SCHEMBL29853525 0.91 PTK2 (1.00) PTK2AURKAJAK2STK16CDKL5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250214963-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER INC. 2025-07-03 — — US disclosed
US-20240109862-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER INC. 2024-04-04 — — US disclosed
US-20220251066-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER INC. 2022-08-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214963-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR PTK2 4052/4885AURKA 1617/4885JAK2 990/4885
US-20240109862-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR PTK2 4052/4885AURKA 1617/4885JAK2 990/4885
US-20220251066-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR PTK2 4052/4885AURKA 1617/4885JAK2 990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback